Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated with Treatment

Register Now

September 13, 2022 5:00 - 6:00 PM

Overview

The management of advanced non–small cell lung cancer (NSCLC) has evolved over the past decade to incorporate a wide variety of actionable therapeutic targets into the standard of care. Now, nurses and physicians must contend with rapidly changing best practices with respect to molecular testing, treatment selection, and management of adverse events.

In this live, virtual symposium, experts in the management of NSCLC will discuss up-to-date principles for treating patients with actionable targets for therapy, including key challenges relating to molecular testing, selection of therapy, and managing the complications of therapy. This discussion will be presented as case scenarios supplemented by evidence-based presentations.

Benefits of Attending

• Answer your big questions about how to use targeted therapy
• Sort out molecular testing in patients with lung cancer
• Learn how to manage challenging toxicities associated with new therapies

Target Audience

This educational program is directed toward nurses, nurse practitioners, physician assistants, oncologists, and other clinicians involved in the management of lung cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Determine the rationale for timely and optimal molecular testing in patients with NSCLC across lines of care
• Describe clinical trial results on the use of current and emerging targeted therapies in NSCLC
• Explain treatment-related toxicities that may occur with the use of targeted therapies among patients with lung cancer
• Implement nursing strategies into clinical practice to optimize care for patients with NSCLC whose tumors possess molecular alterations, including approaches to mitigate the impact of toxicities on outcomes

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.